Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 89.3% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -96.5% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -96.1% | – | – | – |
| EPS Diluted | -0.98 | -2.63 | -2.3 | -1.59 |
| % Growth | 62.7% | -14.3% | -44.7% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |